Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | CCR2 | P41597 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | F10 | P00742 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6308930 | 0.88 | MAPT (0.55) | HPGDSMN1; SMN2L3MBTL1CCR2MAPT | |
| SCHEMBL6308907 | 0.86 | MAPT (0.59) | HPGDSMN1; SMN2L3MBTL1CCR2MAPT | |
| SCHEMBL7234016 | 0.86 | MAPT (0.55) | HPGDSMN1; SMN2L3MBTL1CCR2MAPT | |
| SCHEMBL6596771 | 0.86 | CCR2 (0.47) | HPGDSMN1; SMN2L3MBTL1CCR2MAPT | |
| SCHEMBL6300567 | 0.85 | CCR2 (0.67) | HPGDSMN1; SMN2L3MBTL1CCR2MAPT | |
| SCHEMBL6598529 | 0.85 | F10 (0.52) | SMN1; SMN2CCR2MAPTTP53F10 | |
| SCHEMBL6357264 | 0.76 | CCR2 (0.65) | CCR2MAPTKMT2A | |
| SCHEMBL6775247 | 0.75 | CCR2 (0.65) | SMN1; SMN2CCR2MAPTTP53F10 | |
| SCHEMBL6596097 | 0.74 | CCR2 (0.55) | CCR2 | |
| SCHEMBL6595233 | 0.74 | MAPT (0.53) | L3MBTL1CCR2MAPTTP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6953809-B2 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED (GB) | 2005-10-11 | — | — | US | disclosed |
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | ZENECA LIMITED | 2003-06-26 | — | — | US | disclosed |
| US-6569888-B1 | Such as ethyl-N-(dichlorobenzyl)-4-(3-hydroxypropylthio) indole-2-carboxylate; for treatment of arthritis | ASTRAZENECA AB (SE) | 2003-05-27 | — | — | US | disclosed |
| US-6441004-B1 | INDOLE DERIVATIVES AS ANTIINFLAMMATORY AGENTS | ZENECA LIMITED (GB) | 2002-08-27 | — | — | US | disclosed |
| EP-1150954-A1 | ANTI-IMFLAMMATORY INDOLE DERIVATIVES | AstraZeneca AB (SE) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000046198-A1 | ANTI-INFLAMMATORY INDOLE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-08-10 | — | — | WO | disclosed |
| EP-1003504-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | AstraZeneca UK Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999007351-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ZENECA LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119830-A1 | Monocyte chemoattractant protein-1 inhibitor compounds | CCL2, CCL11, CCR1 | HPGD 1094/4885SMN1; SMN2 3610/4885L3MBTL1 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.